The Financial Post, which broke the story on January 17, reported that Life Technologies brought in the advisors to generate interest for a possible sale, noting that potential buyers could include private equity firms or life science industry companies. The newspaper stated that pricing could be in the range of $65–$75 per share, resulting in a transaction valued at $13.7–$15.7 billion. Jefferies & Co. suggested that the deal could have a price range of $50–$60 per share. Life Technologies’ stock closed at $54.97 on January 17. Reuters reported on January 30 that Thermo Fisher Scientific, KKR & Co., Blackstone Group, Bain Capital and TPG Capital have indicated interest.